Hokuyaku Takeyama Holdings, Inc operates within the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hokuyaku Takeyama Holdings, Inc with three other
drug stores in Asia:
Hai-O Enterprise Berhad
sales of 404.24 million Malaysian Ringgits [US$95.70 million]
of which 76%
was Multi-Level Marketing),
Hua Xia Healthcare Holdings Limited
of Hong Kong
(269.52 million Hong Kong Dollars [US$34.51 million]
of which 348%
was Pharmaceutical Wholesale), and
Hin Sang Group (International) Holding Co Ltd
based in Hong Kong
(201.82 million Hong Kong Dollars [US$25.84 million]
of which 89%
was Product Development Segment).
During the year ended March of 2017, sales at
Hokuyaku Takeyama Holdings, Inc were ¥228.71 billion (US$2.02 billion).
a very small
increase of 1.6%
versus 2016, when the company's sales were ¥225.15 billion.
Sales of Medical Equipment Business saw an increase
that was more than double the company's growth rate: sales were up
11.9% in 2017, from
¥46.40 billion to ¥51.90 billion.
Hokuyaku Takeyama Holdings, Inc also saw significant increases in sales in
Dispensing Business (up 4.7% to ¥14.04 billion)
Nursing Care Business (up 8.5% to ¥2.62 billion)
Not all segments of Hokuyaku Takeyama Holdings, Inc experienced an increase in sales in 2017:
sales of Ict Bussiness fell 28.8% to ¥704.00 million.
(However, this segment's sales were only a very small portion of the company's overall sales).
Hokuyaku Takeyama Holdings, Inc also experienced decreases in sales in
Pharmaceutical Business (down 1.5% to ¥159.40 billion)
Other (down 10.2% to ¥44.00 million)